Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma
暂无分享，去创建一个
Michael L. Wang | E. Bone | J. Westin | S. Neelapu | A. Whale | P. Beer | R. Davis | H. Lee | F. Hagemeister | F. Samaniego | L. Nastoupil | N. Fowler | Letitia Lensun | H. McElwaine-Johnn | A. Cecil | James Dow | K. Haque | F. Silva